Publications by authors named "Judith Sebolt-Leopold"

Claim this Profile
A
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance.
Christopher E Whitehead, Elizabeth K Ziemke, Christy L Frankowski-McGregor, Rachel A Mumby, June Chung, Judith S Sebolt-Leopold

Nat Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence.
Monika Sharma, Ivana Barravecchia, Robert Teis, Jeanette Cruz, Rachel Mumby, Judith S Sebolt-Leopold

Mol Cancer Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of NF1 in Melanoma Confers Sensitivity to SYK Kinase Inhibition.
Cara Abecunas, Christopher E Whitehead, Elizabeth K Ziemke, Douglas G Baumann, Christy L Frankowski-McGregor, Judith S Sebolt-Leopold

Cancer Res· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deciphering the Complexity of MEK Mutations in the Clinic.
Christopher E Whitehead, Judith S Sebolt-Leopold

Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable.
Patricia M LoRusso, Judith S Sebolt-Leopold

N Engl J Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers.
Joel D Maust, Christy L Frankowski-McGregor, Armand Bankhead, Diane M Simeone, Judith S Sebolt-Leopold

Mol Cancer Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic Mutants of : A Trilogy Unfolds.
Joel D Maust, Christopher E Whitehead, Judith S Sebolt-Leopold

Cancer Discov· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Preclinical Models to Understand and Treat Colorectal Cancer.
Judith S Sebolt-Leopold

Clin Colon Rectal Surg· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
Joseph Dosch, Elizabeth Ziemke, Shanshan Wan, Kathryn Luker, Theodore Welling, Judith Sebolt-Leopold

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor.
Kavya Ramkumar, Soma Samanta, Anahita Kyani, Suhui Yang, Shuzo Tamura, Judith S Sebolt-Leopold

Nat Commun· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
Elizabeth K Ziemke, Joseph S Dosch, Joel D Maust, Amrith Shettigar, Ananda Sen, Judith S Sebolt-Leopold

Clin Cancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.
Joseph S Dosch, Elizabeth K Ziemke, Amrith Shettigar, Alnawaz Rehemtulla, Judith S Sebolt-Leopold

Cancer Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1.
Huabing Zhang, Sadeesh K Ramakrishnan, Daniel Triner, Brook Centofanti, Dhiman Maitra, Judith S Sebolt-Leopold

Sci Signal· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor.
Marcian E Van Dort, Stefanie Galbán, Hanxiao Wang, Judith Sebolt-Leopold, Christopher Whitehead

Bioorg Med Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ERK activation is required for CCK-mediated pancreatic adaptive growth in mice.
Bryan J Holtz, Kevin B Lodewyk, Judith S Sebolt-Leopold, Stephen A Ernst, John A Williams

Am J Physiol Gastrointest Liver Physiol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAPK signaling is required for dedifferentiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice.
Meredith A Collins, Wei Yan, Judith S Sebolt-Leopold, Marina Pasca di Magliano

Gastroenterology· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model.
Benjamin A Hoff, Mahaveer S Bhojani, John Rudge, Thomas L Chenevert, Charles R Meyer

NMR Biomed· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Terence M Williams, Athena R Flecha, Paul Keller, Ashwin Ram, David Karnak, Judith Sebolt-Leopold

Mol Cancer Ther· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.
Daniel Gioeli, Winfried Wunderlich, Judith Sebolt-Leopold, Stefan Bekiranov, Julia D Wulfkuhle

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment.
Craig J Galbán, Thomas L Chenevert, Charles R Meyer, Christina Tsien, Theodore S Lawrence, Judith S Sebolt-Leopold

Clin Cancer Res· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies.
Katherine A Rauen, Anuradha Banerjee, W Robert Bishop, Jennifer O Lauchle, Frank McCormick, Judith Sebolt-Leopold

Am J Med Genet C Semin Med Genet· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
Katherine A Rauen, Lisa Schoyer, Frank McCormick, Angela E Lin, Judith E Allanson, Judith Sebolt-Leopold

Am J Med Genet A· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
Jennifer O Lauchle, Doris Kim, Doan T Le, Keiko Akagi, Michael Crone, Judith Sebolt-Leopold

Nature· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.
Stephen D Barrett, Alexander J Bridges, David T Dudley, Alan R Saltiel, James H Fergus, Judith Sebolt-Leopold

Bioorg Med Chem Lett· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway.
Judith S Sebolt-Leopold

Clin Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis